Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

Nature

Volumn 431, Issue 7010, 2004, Pages 805-810

  Arrasate, Montserrat ^a,b   Mitra, Siddhartha ^a   Schweitzer, Erik S ^c   Segal, Mark R ^a   Finkbeiner, Steven ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Programs in Neuroscience   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOMATION; FUNCTIONS; PATHOLOGY; PROTEINS; RISK ASSESSMENT;

COPING RESPONSE; INCLUSION BODY FORMATION; MUTANTS; SURVIVAL ANALYSIS;

NEUROLOGY;

HUNTINGTIN; MUTANT PROTEIN; POLYGLUTAMINE;

MEDICINE;

ADAPTATION; ANIMAL CELL; CELL INCLUSION; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; EMBRYO; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MICROSCOPY; MUTATION; NERVE CELL NECROSIS; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN MODIFICATION; RAT; REVIEW;

ANIMALS; CELL DEATH; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; HUMANS; HUNTINGTON DISEASE; INCLUSION BODIES; MODELS, BIOLOGICAL; MUTATION; NEOSTRIATUM; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PEPTIDES; RATS;

ANIMALIA;

EID: 7244236320     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature02998     Document Type: Review

References (50)

1. Davies, S. W. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548 (1997).
2. Becher, M. W. et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy-correlation between the density of inclusions and IT-15 CAG triplet repeat length. Neurobiol. Dis. 4, 387-397 (1998).
3. DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993 (1997).
4. Ordway, J. M. et al. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 91, 753-763 (1997).
5. Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M. E. Huntingtin acts in the nucleus to induce apoptosis, but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66 (1998).
6. Klement, I. A. et al. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95, 41-53 (1998).
7. Cummings, C. J. et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24, 879-892 (1999).
8. Taylor, J. P. et al. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum. Mol. Genet. 12, 749-757 (2003).
9. Shimohata, T. et al. Expanded polyglutamine stretches form an 'aggresome'. Neurosci. Lett. 323, 215-218 (2002).
10. Sisodia, S. S. Nuclear inclusions in glutamine repeat disorders: Are they pernicious, coincidental or beneficial? Cell 95, 1-4 (1998).
11. Bence, N. F., Sampat, R. M. & Kopito, R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555 (2001).
12. Ross, C. A. Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases. Neuron 19, 1147-1150 (1997).
13. Poirier, M. A. et al. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277, 41032-41037 (2002).
14. Chen, S., Berthelier, V., Yang, W. & Wetzel, R. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J. Mol. Biol. 311, 173-182 (2001).
15. Wyttenbach, A. et al. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl Acad. Sci. USA 97, 2898-2903 (2000).
16. Muchowski, P. J., Ning, K., D'Souza-Schorey, C. & Fields, S. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc. Natl Acad. Sci. USA 99, 727-732 (2002).
17. Perutz, M. F. & Windle, A. H. Cause of neural death in neurodegenerative disease attributable to expansion of glutamine repeats. Nature 412, 143-144 (2001).
18. Arrasate, M., Brooks, L., Chang, P., Mitra, S. & Finkbeiner, S. Longitudinal analysis to identify pathogenic factors in a striatal model of Huntington's disease. Soc. Neurosci. Abstr. 29, 209.8 (2003).
19. Collett, D. Modeling Survival Data in Medical Research (Chapman & Hall, London, 1994).
20. Therneau, T. M. & Grambsch, P. M. Modeling Survival Data: Extending the Cox Model (Springer, New York, 2000).
21. Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D. & Housman, D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl Acad. Sci. USA 96, 11404-11409 (1999).
22. Goldberg, Y. P. et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genet. 13, 442-449 (1996).
23. Scherzinger, E. et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549-558 (1997).
24. Wellington, C. L. et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine. J. Biol. Chem. 273, 9158-9167 (1998).
25. Kim, Y. J. et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl Acad. Sci. USA 98, 12784-12789 (2001).
26. Mende-Mueller, L. M., Toneff, T., Hwang, S. R., Chesselet, M. F. & Hook, V. Y. H. Tissue-specific proteolysis of huntingtin (htt) in human brain: Evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum. J. Neurosci. 21, 1830-1837 (2001).
27. Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506 (1996).
28. Campbell, R. E. et al. A monomeric red fluorescent protein. Proc. Natl Acad. Sci. USA 99, 7877-7882 (2002).
29. Strebel, A., Harr, T., Bachmann, F., Wernli, M. & Erb, P. Green fluorescent protein as a novel tool to measure apoptosis and necrosis. Cytometry 43, 126-133 (2001).
30. MacDonald, M. E. in Trinucleotide Diseases and Instability (ed. Oostra, B. A.) 47-75 (Springer, Berlin, 1998).
31. Clarke, G. et al. A one-hit model of cell death in inherited neuronal degenerations. Nature 406, 195-199 (2000).
32. Reiner, A. et al. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl Acad. Sci. USA 85, 5733-5737 (1988).
33. Richfield, E. K., Maguire-Zeiss, K. A., Vonkeman, H. E. & Voorn, P. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann. Neurol. 38, 852-861 (1995).
34. Rajan, R. S., Illing, M. E., Bence, N. F. & Kopito, R. R. Specificity in intracellular protein aggregation and inclusion body formation. Proc. Natl Acad. Sci. USA 98, 13060-13065 (2001).
35. Moulder, K. L., Onodera, O., Burke, J. R., Strittmatter, W. J. & Johnson, E. M. Jr Generation of neuronal intranuclear inclusions by polyglutamine-GFP: Analysis of inclusion clearance and toxicity as a function of polyglutamine length. J. Neurosci. 19, 705-715 (1999).
36. Gutekunst, C. A. et al. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology. J. Neurosci. 19, 2522-2534 (1999).
37. Preisinger, E., Jordan, B. M., Kazantsev, A. & Housman, D. Evidence for a recruitment and sequestration mechanism in Huntington's disease. Phil. Trans. R. Soc. Lond. B 354, 1029-1034 (1999).
38. Kuemmerle, S. et al. Huntingtin aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 46, 842-849 (1999).
39. Kim, M. et al. Mutant huntingtin expression in clonal striatal cells: Dissociation of inclusion formation and neuronal survival by caspase inhibition. J. Neurosci. 19, 964-973 (1999).
40. Hack, N. J. et al. Green fluorescent protein as a quantitative tool. J. Neurosci. Methods 95, 177-184 (2000).
41. Yoo, S.-Y. et al. SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 37, 383-401 (2003).
42. Persichetti, F. et al. Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiol. Dis. 3, 183-190 (1996).
43. Kegel, K. B. et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 277, 7466-7476 (2002).
44. Peters, M. F. et al. Nuclear targeting of mutant huntingtin increases toxicity. Mol. Cell. Neurosci. 14, 121-128 (1999).
45. Ravikumar, B. et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nature Genet. 36, 585-595 (2004).
46. Sánchez, I., Mahlke, C. & Yuan, J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421, 373-379 (2003).
47. Apostol, B. L. et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc. Natl Acad. Sci. USA 100, 5950-5955 (2003).
48. Tanaka, M. et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nature Med. 10, 148-154 (2004).
49. Finkbeiner, S. et al. CREB: A major mediator of neuronal neurotrophin responses. Neuron 19, 1031-1047 (1997).
50. Aiken, C. T., Tobin, A. J. & Schweitzer, E. S. A cell-based screen for drugs to treat Huntington's disease. Neurobiol. Dis. 16, 546-555 (2004).